These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 29095907)
1. Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign. Diallo AO; Soeters HM; Yameogo I; Sawadogo G; Aké F; Lingani C; Wang X; Bita A; Fall A; Sangaré L; Ouédraogo-Traoré R; Medah I; Bicaba B; Novak RT; PLoS One; 2017; 12(11):e0187466. PubMed ID: 29095907 [TBL] [Abstract][Full Text] [Related]
2. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241 [TBL] [Abstract][Full Text] [Related]
3. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. Kristiansen PA; Ba AK; Ouédraogo AS; Sanou I; Ouédraogo R; Sangaré L; Diomandé F; Kandolo D; Saga IM; Misegades L; Clark TA; Préziosi MP; Caugant DA BMC Infect Dis; 2014 Dec; 14():663. PubMed ID: 25472422 [TBL] [Abstract][Full Text] [Related]
4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization. Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso. Zoma RL; Walldorf JA; Tarbangdo F; Patel JC; Diallo AO; Nkwenkeu SF; Kambou L; Nikiema M; Ouedraogo A; Bationo AB; Ouili R; Badolo H; Sawadogo G; Krishnaswamy A; Hatcher C; Hyde TB; Aké F; Novak RT; Wannemuehler K; Mirza I; Medah I; Soeters HM J Infect Dis; 2019 Oct; 220(220 Suppl 4):S233-S243. PubMed ID: 31671442 [TBL] [Abstract][Full Text] [Related]
6. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256 [TBL] [Abstract][Full Text] [Related]
7. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018. Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448 [TBL] [Abstract][Full Text] [Related]
8. Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso. Nkwenkeu SF; Jalloh MF; Walldorf JA; Zoma RL; Tarbangdo F; Fall S; Hien S; Combassere R; Ky C; Kambou L; Diallo AO; Krishnaswamy A; Aké FH; Hatcher C; Patel JC; Medah I; Novak RT; Hyde TB; Soeters HM; Mirza I BMC Public Health; 2020 Feb; 20(1):254. PubMed ID: 32075630 [TBL] [Abstract][Full Text] [Related]
9. Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso. Colombini A; Trotter C; Madrid Y; Karachaliou A; Preziosi MP Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S473-82. PubMed ID: 26553677 [TBL] [Abstract][Full Text] [Related]
10. Serogroup W Meningitis Outbreak at the Subdistrict Level, Burkina Faso, 2012. Cibrelus L; Medah I; Koussoubé D; Yélbeogo D; Fernandez K; Lingani C; Djingarey M; Hugonnet S Emerg Infect Dis; 2015 Nov; 21(11):2063-6. PubMed ID: 26488128 [TBL] [Abstract][Full Text] [Related]
11. Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt. Jackson ML; Diallo AO; Médah I; Bicaba BW; Yaméogo I; Koussoubé D; Ouédraogo R; Sangaré L; Mbaeyi SA PLoS One; 2018; 13(10):e0206117. PubMed ID: 30359419 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257 [TBL] [Abstract][Full Text] [Related]
16. Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine. Topaz N; Kristiansen PA; Schmink S; Congo-Ouédraogo M; Kambiré D; Mbaeyi S; Paye M; Sanou M; Sangaré L; Ouédraogo R; Wang X Microb Genom; 2020 Dec; 6(12):. PubMed ID: 33332261 [TBL] [Abstract][Full Text] [Related]